These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 12195454

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
    Mezei Z, Bereczki D, Csiba L, Csépány T.
    Ideggyogy Sz; 2006 Nov 20; 59(11-12):442-7. PubMed ID: 17203882
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Betaferon in the treatment of multiple sclerosis.
    Vidović M, Sinanović O, Burina A, Hudić J, Sehanović A.
    Acta Clin Croat; 2009 Sep 20; 48(4):419-21. PubMed ID: 20405637
    [Abstract] [Full Text] [Related]

  • 25. Once-weekly 22microg subcutaneous IFN-beta-1a in secondary progressive MS: a 3-year follow-up study on brain MRI measurements and serum MMP-9 levels.
    Wu X, Kuusisto H, Dastidar P, Huhtala H, Nikkari ST, Ukkonen M, Höyhtyä M, Elovaara I.
    Acta Neurol Scand; 2007 Jul 20; 116(1):43-8. PubMed ID: 17587254
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Interferon-beta response in multiple sclerosis associated with pre-treatment disability].
    Fernandez-Fernandez O, Fernandez-Sanchez VE, Mayorga C, Guerrero-Fernandez M, Leon A, Tamayo-Toledo JA, Alonso A, Romero F, Leyva L, Luque G, de Ramon E.
    Rev Neurol; 2007 Jul 20; 43(6):322-9. PubMed ID: 16981161
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G, Barbarash O, Casset-Semanaz F, Jaber A, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B, RNF Study Group.
    Clin Ther; 2007 Jun 20; 29(6):1128-45. PubMed ID: 17692727
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
    Sorensen PS, Koch-Henriksen N, Flachs EM, Bendtzen K.
    Mult Scler; 2008 Jul 20; 14(6):837-42. PubMed ID: 18505772
    [Abstract] [Full Text] [Related]

  • 37. Effects of relapsing-remitting multiple sclerosis treatment with interferon beta-1b results of a three-year follow-up study.
    Jesić A, Stefanović D, Delibasić N, Semnic M, Sakallasz L, Dobrenov D, Zivanović Z, Rabi-Zikić T, Zikić M.
    Acta Clin Croat; 2009 Jun 20; 48(2):183-6. PubMed ID: 19928420
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A, Bilińska M, Gruszka E, Dubik-Jezierzańska M.
    Pol Merkur Lekarski; 2005 Nov 20; 19(113):654-8. PubMed ID: 16498805
    [Abstract] [Full Text] [Related]

  • 40. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H, Yinshan Zhao, Devonshire V.
    Mult Scler; 2008 Apr 20; 14(3):314-24. PubMed ID: 18208898
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.